Navigation Links
Progress after recent breakthrough which opened new chapter in anti-cancer cell therapies
Date:5/22/2013

May 22, 2012 (Hackensack, NJ) John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will bring together leading cancer experts, for presentation and discussion of the latest developments and implications of cell therapy and interventional immunology in oncology, on Friday, June 7 from 7:00am to 1:30pm.

"I'm excited to bring together some of the nation's top immunology experts to review the latest developments and implications of cell therapies in oncology, both in solid and liquid tumors," said Andre Goy M.D., Cancer Center Director, and Chief of lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates. "This will provide an opportunity to see where the field is going and discuss some of the mechanisms and applications of T-cell manipulation as a promising tool against a number of cancers. The preliminary results seen with these modified T-cells will likely be revolutionary in the treatment of cancer".

The conference, titled "Cell Therapy and Interventional Immunology: Current Developments and Implications", is designed for hematologists, oncologists, physicians, and medical professionals. Given the enormous impact and growing interest in those therapies, the conference will also be offered to patients and caregivers through live online streaming. Speakers will cover the biology and manufacturing aspects of the chimeric antigenic receptor (CAR) modified T-cells as well as other manipulation of T-cells and the immune system, which for the first time, seem to be translating into impressive activity in the clinic.

The conference speakers and presentations include:

  • Catherine Bollard, MBChB, M.D., Professor of Pediatrics, Medicine, and Pathology & Immunology, Texas Children's Cancer Center, Baylor College of Medicine: Anti-EBV T-Cells and CAR T-Cells and Their Applications in Hematological Malignancies
  • Renier J. Brentjens, M.D., Ph.D., Leukemia Service, Memorial Sloan-Kettering Cancer Center: CAR Modified T-Cells for the Treatment of Cancer: Preclinical and Clinical Outcomes
  • Daniel H. Fowler M.D., Senior Investigator, Center for Cancer Research. National Cancer Institute: TH-2 Amplification and Other strategies to Reduce GVHD and Improve Outcome in Allogeneic Transplantations.
  • James N. Kochenderfer, M.D., Assistant Clinical Investigator, Center for cancer Research, National Cancer Institute: Autologous and Donor Derived Anti-CD19 CAR T-Cells Applications in non-Hodgkin Lymphoma and CLL
  • Cameron J. Turtle, M.D., Ph.D., Acting Instructor, University of Washington and Research Associate, Fred Hutchinson Cancer Research Center: Engineered Antigen Presenting Cells and T-Cells for Anti-Cancer Therapy

"Conferences such as this help physicians, medical professionals, as well as patients and caregivers to gain a better understanding of promising new treatment options, resulting in better clinical outcomes," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor, and Vice President of Cancer Services and President of Regional Cancer Care Associates, "John Theurer Cancer Center is committed to providing these conferences to improve patient care and education."


'/>"/>

Contact: Amy Leahing
ALeahing@hackensackumc.org
305-458-0599
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency
2. Mirena IUD Lawyers at Gilman Law LLP, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Anticipates Progress in Newly Established Mirena Federal Litigation
3. 30 Years of Orphan Drug Act, Combined with Science and Advocacy, Reflect Dramatic Progress in a Rare Lung Disease, Pulmonary Hypertension Association Says
4. Study evaluates effect of different supplements on reducing risk of progression to advanced AMD
5. Nina Brown Launches New Website for Spiritual Progressives
6. Despite superbug crisis, progress in antibiotic development alarmingly elusive
7. Progressive Dental Marketing Is Bringing Online Dental Marketing to Oregon for Dental Professionals Specializing in Laser Dentistry and Dental Implants
8. New findings on the brains immune cells during Alzheimers disease progression
9. Progressive Dental Marketing Is Bringing Online Dental Marketing to Oregon for Dental Professionals Specializing in Laser Dentistry and Dental Implants
10. Progressive Dental Marketing Is Bringing Online Dental Marketing to Washington for Dental Professionals Specializing in Laser Dentistry and Dental Implants
11. Progressive Dental Marketing Is Bringing Online Dental Marketing to Vancouver, B.C. for Dental Professionals Specializing in Laser Dentistry and Dental Implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: